4/20/19 MEDICAL SYSTEM CHALLENGES 16 ADVOCACY NEEDS Research - - PDF document

4/20/19 1

16

MEDICAL SYSTEM CHALLENGES

17

ADVOCACY NEEDS

Research Funding through the Special Diabetes Program Regulatory Healthcare Coverage and Choice

COMMUNITY SUPPORT

Mentoring Event Participation

4/20/19 2

19

T1D Research

100,000 200,000 300,000 400,000 500,000 600,000 700,000 2010 2020 2030 2040 2050

Projected number of youth with T1D

Year

Diabetes Care 35 (12), 2515 (2012) 20

PREVENTION

T1D IS ON THE RISE

Number of people in the US <20 years old projected to develop T1D in the coming decades

The incidence of T1D among young people in the U.S. is projected to roughly triple by 2050

Immunotherapy

Intercepting the immune attack on beta cells

21

4/20/19 3

IMMUNOTHERAPY

22

T1D is one of the only major autoimmune diseases that still does not have a drug therapy to stave off, slow or cure the

• illness. But we are getting close.

We have found, created and are testing drugs that are showing – in early clinical trials -- that they can and are able to:

• Trick the body into protecting instead of attacking beta cells
• Slow the progression of T1D
• Help the body create its own insulin

A break in any of these products would be life changing for millions. And could serve as a working cure for T1D.

23

Prevention

Prevent or delay insulin dependence

24

Today, we are working – racing – with teams

• f experts around the world, to:

Regenerate Beta Cells Replace Beta Cells

Keep them healthy, improve their function, and help them reproduce. Make beta cells, ensure the body does not reject them, and shield them from attack.

This research is accelerating, with new discoveries daily. We need to do

• more. With healthy beta cells, a person’s body would once again normalize

its blood glucose levels – on its own. If we can save Beta Cells, we can cure T1D.

BETA CELLS

4/20/19 4

25

A DECADE OF PROGRESS, MORE TO COME

ARTIFICIAL PANCREAS

• Multiple advanced systems in

development

• More automated and user friendly
• Smaller form factor
• Single device
• And more choices for patients
• JDRF Open Protocol Initiative

“I am thinking about diabetes 50% less of the time, which enables me to focus on what I want to do in life.” Kady Helme // AP Trial Participant

• Daily pill
• Avoids high blood sugar
• Improved time in range, body weight, and

blood pressure – no increase in hypoglycemia

• If approved, 1st ever therapy developed

for T1D before T2D

26

HbA1c

FDA 2019

A pill to dodge high blood sugars

GL GLUC UCOS OSE CONT ONTOR ORL INNOVATION IS ALL AROUND US

27

4/20/19 5

GET INVOLVED

28

CALL TO ACTION

Accelerating Progress 29

Be Active Seek Perspectives

Continue to Learn

• If you haven’t already, please sign up

to become a JDRF Advocate at www.jdrf.org/join

• If you’re already an Advocate, please respond to all alerts
• Share any connections with Congress, federal officials,

health plans and large employers with our team. Who you know matters!

GET INVOLVED! WE NEED YOUR VOICE!

30

4/20/19 6

31

WE CAN CHANGE THE FUTURE FOR PEOPLE WITH T1D!!!

THANK YOU